SCHEMBL5886476

SCHEMBL5886476

COc1ccc2nc3ccc4c(OC)ccc(Cl)c4c3nc2c1C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 2/20 0.42
HSD17B10 Q99714 1/20 0.42
KMT2A Q03164 5/20 0.39
MEN1 O00255 4/20 0.39
MAPT P10636 2/20 0.39
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
CRHBP P24387 1/20 0.36
CRHR2 Q13324 1/20 0.36
NQO2 P16083 1/20 0.35
DHODH Q02127 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
ALOX15 P16050 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5886247 0.80 CA12 (0.51) ALDH1A1KDM4EHSD17B10KMT2AMEN1
SCHEMBL17415836 0.76 MAPT (0.58) ALDH1A1KDM4EKMT2AMEN1MAPT
SCHEMBL7067026 0.72 ALDH1A1 (0.50) ALDH1A1KDM4EHSD17B10KMT2AMEN1
SCHEMBL5886404 0.70 CA12 (0.45) ALDH1A1KDM4EHSD17B10KMT2AMEN1
SCHEMBL27413425 0.70 ALDH1A1 (0.51) ALDH1A1KDM4EHSD17B10KMT2AMEN1
SCHEMBL3057430 0.70 ALDH1A1 (0.63) ALDH1A1KDM4EHSD17B10MAPTCA12
SCHEMBL23751978 0.69 MAPT (0.42) ALDH1A1KDM4EHSD17B10KMT2AMEN1
SCHEMBL5886266 0.69 CA12 (0.44) ALDH1A1KDM4EHSD17B10KMT2AMEN1
SCHEMBL7067506 0.68 ESR1 (0.42) ALDH1A1KDM4EHSD17B10KMT2AMEN1
SCHEMBL5886264 0.68 CA12 (0.42) ALDH1A1KDM4EHSD17B10KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030139409-A1 Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II XENOVA LIMITED (GB) 2003-07-24 US claimed
US-7132419-B2 Pharmaceutical compounds XENOVA LIMITED (GB) 2006-11-07 US disclosed
US-20050143383-A1 Pharmaceutical compounds XENOVA LIMITED (GB) 2005-06-30 US disclosed
US-20030139409-A1 Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II XENOVA LIMITED (GB) 2003-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143383-A1 Pharmaceutical compounds CHRNA10, OPRM1, SCN10A ALDH1A1 3766/4885KDM4E 3704/4885HSD17B10 187/4885
US-20030139409-A1 Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II TOP1, TOP2A, TOP2B ALDH1A1 2334/4885KDM4E 1785/4885HSD17B10 257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.